Table 1 Clinicopathologic features of 135 metaplastic breast cancer patients
Characteristic | n (%) |
|---|---|
Age at diagnosis (y) | |
Median (range); mean ± SD | 52 (22–88); 52.27 ± 13.91 |
Menopausal status | |
Premenopausal | 55 (40.7) |
Postmenopausal | 80 (59.3) |
Laterality | |
Right breast | 64 (47.4) |
Left breast | 71 (52.6) |
pT sizea (cm); median (range) | 4(1–17) |
≤ 4 cm | 65 (48.1) |
> 4 cm | 60 (44.5) |
Unknown | 10 (7.4) |
pT stage | |
T1 | 8 (5.9) |
T2 | 62 (45.9) |
T3 | 24 (17.8) |
T4 | 31 (23.0) |
Unknown | 10 (7.4) |
pN stage | |
N0 | 68 (50.4) |
N1 | 29 (21.5) |
N2 | 18 (13.3) |
N3 | 4 (3.0) |
Unknown | 16 (11.8) |
pN+; median(range) (n = 51) | 3 (1–18) |
Capsular invasion in pN+ patients (n = 51) | |
Present | 34 (66.7) |
Absent | 17 (33.3) |
LVI | |
Present | 59 (43.7) |
Absent | 74 (54.8) |
Unknown | 2 (1.5) |
Tumor grade | |
II | 22 (16.3) |
III | 113 (83.7) |
Initial TNM stage | |
Stage I | 5 (3.7) |
Stage II | 66 (49.0) |
Stage III | 47 (34.8) |
Stage IV | 11 (8.1) |
Unknown | 6 (4.4) |
Ki-67%, median(range) | 45 (10–88) |
≤ 45% | 76 (56.3) |
> 45% | 53 (39.3) |
Unknown | 6 (4.4) |
ER status | |
Negative | 112 (83.0) |
Positive | 23 (17.0) |
PR status | |
Negative | 107 (79.3) |
Positive | 28 (20.7) |
HER-2 status | |
Negative | 113 (83.7) |
Positive | 22 (16.3) |
Molecular subtype | |
LA | 1 (0.7) |
LB | 31 (23.0) |
HER2 enriched | 14 (10.3) |
TN | 89 (66.0) |
Histologic subtype of MetBC | |
Squamous cell carcinoma | 101 (74.8) |
Carcinoma with chondroid and/or osseous differentiation | 18 (13.3) |
Spindle cell carcinoma | 10 (7.4) |
Low-grade adenosquamous carcinoma | 6 (4.5) |
Recurrence after curative surgery (n = 119) | |
Yes | 41 (34.5) |
No | 78 (65.5) |
Recurrence sites (n = 41) | |
Lung ± visceral/bone/brain metastases | 24 (58.5) |
Locoregional recurrence only | 11 (26.8) |
Contralateral breast | 4 (9.8) |
Bone only | 2 (4.9) |